undamentalytics Newsletter
Sign in

Immuneering Corp (IMRX) stock

Add to watchlist

Add holding +

NASDAQ: IMRX Nasdaq Biotechnology Next results ~January 25, 2027

Immuneering Corp is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Immuneering Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders6 buying, 0 selling7 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds73 adding, 41 cuttingOf 22 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~January 25, 2027 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 21% in the quarter to 2026-09-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Immuneering Corp's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Loss-making. Operating margin is -12328770.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 12319113.2 points on a year ago.
  • Burning cash. Free cash flow was -10809489.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 1128507.7% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 20.4% in a year.

Latest results: FY2023 Q4

Filed March 1, 2024
Earnings per share
-$0.37 against an average estimate of -$0.31: missed by 21.0%
Share reaction
-6.1% in the first session after the results on October 29, 2026, against -2.1% for the S&P 500
Next report
October 29, 2026; average EPS estimate -$0.34

Immuneering's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.8%
  • 1 week-5.9%
  • 1 month-14.3%
  • This year-47.0%
  • 1 year-49.2%
  • 5 years-88.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-1.87

Growth

Share count change
+20.4%

Earnings

Last results
October 29, 2026
Next results (est.)
January 25, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Immuneering Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.12 +12% — 0%
Next −$1.26 −12% $20m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.5% on 90 days ago. In the last 30 days, 3 analysts raised Immuneering Corp's forecast and 2 cut it.

Consensus EPS forecast Immuneering Corp, last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.11 Current fiscal year, 60 days ago: −$1.12 Current fiscal year, 30 days ago: −$1.12 Current fiscal year, 7 days ago: −$1.12 Current fiscal year, Now: −$1.12 −$1.12 Next fiscal year, 90 days ago: −$1.29 Next fiscal year, 60 days ago: −$1.29 Next fiscal year, 30 days ago: −$1.26 Next fiscal year, 7 days ago: −$1.26 Next fiscal year, Now: −$1.26 −$1.26

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.11−$1.29
60 days ago −$1.12−$1.29
30 days ago −$1.12−$1.26
7 days ago −$1.12−$1.26
Now −$1.12−$1.26

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.31 −$0.37 −21.0%
Jun 2026 −$0.27 −$0.27 −0.5%
Mar 2026 −$0.25 −$0.21 +16.7%
Dec 2025 −$0.31 −$0.18 +42.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026257
  2. Sep 2026257
  3. Aug 2026257
  4. Jul 2026257

Counts of recommendations published by analysts covering Immuneering Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
33.3%
of tradable shares
Days to cover
22.26
at average volume
Short interest, 1 month
+5%
to October 15, 2026
Held by institutions
56%
of shares
Held by insiders
13.8%
of shares
Employees
57
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
IMRX−70%+52%−70%+199%−47%
Industry peers (median)−56%−18%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
IMRX25%50%33%50%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
IMRX−77%−64%−86%−53%−59%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 30, 2021: 97% from September 27, 2021 to August 16, 2024. Getting back needed a 3088% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.42 – $8.33
From 52-week high
−58.1%
vs 50-day average
−17.8%
vs 200-day average
−27.3%
Volatility (1 year)
80%
Beta vs S&P 500
1.14

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.2%
After a week
7 up, 4 down
typical move ±6.0%
After a month
4 up, 7 down
typical move ±34.0%
Results releasedNext dayS&P 500 next day5 days21 days
October 29, 2026 −6.1% −2.1% — —
August 5, 2026 +1.4% −0.4% +15.2% +14.5%
May 15, 2026 −5.3% −1.3% +4.9% −20.2%
March 6, 2026 +12.9% −0.4% +1.4% +5.0%
November 12, 2025 −4.3% −1.6% +6.4% −9.8%
August 13, 2025 −6.5% +0.4% +5.5% +161.2%
May 5, 2025 −4.0% −1.4% −4.0% +58.1%
March 20, 2025 +7.1% −0.3% −1.2% −17.9%
November 13, 2024 +6.0% −0.6% +11.5% −10.7%
August 6, 2024 −6.6% +0.2% −6.6% −2.5%
May 7, 2024 −1.2% +0.1% −3.0% −14.5%
March 1, 2024 −0.8% +0.8% +5.8% −59.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Immuneering Corp
$0 $1M $2M $3M FY21 Q1 FY21 Q4 FY22 Q3 FY23 Q4 Revenue (TTM), FY21 Q1: $2.6M Revenue (TTM), FY21 Q2: $2.8M Revenue (TTM), FY21 Q3: $2.6M Revenue (TTM), FY21 Q4: $2.1M Revenue (TTM), FY22 Q1: $1.5M Revenue (TTM), FY22 Q2: $949.8K Revenue (TTM), FY22 Q3: $506.1K Revenue (TTM), FY22 Q4: $317K Revenue (TTM), FY23 Q1: $133.3K Revenue (TTM), FY23 Q2: $38.8K Revenue (TTM), FY23 Q3: $455 Revenue (TTM), FY23 Q4: $0 $0

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY21 Q1 $2.6M
FY21 Q2 $2.8M
FY21 Q3 $2.6M
FY21 Q4 $2.1M
FY22 Q1 $1.5M
FY22 Q2 $949.8K
FY22 Q3 $506.1K
FY22 Q4 $317K
FY23 Q1 $133.3K
FY23 Q2 $38.8K
FY23 Q3 $455
FY23 Q4 $0
Revenue growth, TTM YoY Immuneering Corp
-100% -50% 0% FY22 Q1 FY22 Q3 FY23 Q1 FY23 Q4 Revenue growth, TTM YoY, FY22 Q1: -41.2% Revenue growth, TTM YoY, FY22 Q2: -65.5% Revenue growth, TTM YoY, FY22 Q3: -80.2% Revenue growth, TTM YoY, FY22 Q4: -84.8% Revenue growth, TTM YoY, FY23 Q1: -91.2% Revenue growth, TTM YoY, FY23 Q2: -95.9% Revenue growth, TTM YoY, FY23 Q3: -99.9% Revenue growth, TTM YoY, FY23 Q4: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY22 Q1 -41.2%
FY22 Q2 -65.5%
FY22 Q3 -80.2%
FY22 Q4 -84.8%
FY23 Q1 -91.2%
FY23 Q2 -95.9%
FY23 Q3 -99.9%
FY23 Q4 -100.0%
Operating margin (TTM) Immuneering Corp
-15000000% -10000000% -5000000% 0% FY21 Q1 FY21 Q3 FY22 Q1 FY22 Q3 FY23 Q1 FY23 Q3 Operating margin (TTM), FY21 Q1: -779.3% Operating margin (TTM), FY21 Q2: -887.7% Operating margin (TTM), FY21 Q3: -1119.4% Operating margin (TTM), FY21 Q4: -1629.2% Operating margin (TTM), FY22 Q1: -2677.5% Operating margin (TTM), FY22 Q2: -4656.7% Operating margin (TTM), FY22 Q3: -9657.5% Operating margin (TTM), FY22 Q4: -16325.8% Operating margin (TTM), FY23 Q1: -40148.0% Operating margin (TTM), FY23 Q2: -142545.9% Operating margin (TTM), FY23 Q3: -12328770.8% -12328770.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY21 Q1 -779.3%
FY21 Q2 -887.7%
FY21 Q3 -1119.4%
FY21 Q4 -1629.2%
FY22 Q1 -2677.5%
FY22 Q2 -4656.7%
FY22 Q3 -9657.5%
FY22 Q4 -16325.8%
FY23 Q1 -40148.0%
FY23 Q2 -142545.9%
FY23 Q3 -12328770.8%
FCF margin (TTM) Immuneering Corp
-15000000% -10000000% -5000000% 0% FY21 Q2 FY21 Q4 FY22 Q2 FY22 Q4 FY23 Q3 FCF margin (TTM), FY21 Q2: -783.6% FCF margin (TTM), FY21 Q3: -1062.5% FCF margin (TTM), FY21 Q4: -1486.2% FCF margin (TTM), FY22 Q1: -2451.5% FCF margin (TTM), FY22 Q2: -4243.7% FCF margin (TTM), FY22 Q3: -8353.9% FCF margin (TTM), FY22 Q4: -14148.4% FCF margin (TTM), FY23 Q1: -35191.2% FCF margin (TTM), FY23 Q2: -123894.9% FCF margin (TTM), FY23 Q3: -10809489.5% -10809489.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q2 -783.6%
FY21 Q3 -1062.5%
FY21 Q4 -1486.2%
FY22 Q1 -2451.5%
FY22 Q2 -4243.7%
FY22 Q3 -8353.9%
FY22 Q4 -14148.4%
FY23 Q1 -35191.2%
FY23 Q2 -123894.9%
FY23 Q3 -10809489.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023
Income
Revenue 2 2 0 0
Gross profit 1 1 0 0
EBITDA −17 −34 −51 −58
Operating income −17 −34 −52 −58
Net income −17 −34 −51 −53
Diluted EPS −$1.72 −$1.23 −$1.91 −$1.88
Growth (year on year)
Revenue — −10.0% −84.8% −100.0%
Margins
Gross margin 44.6% 44.6% 50.1% —
EBITDA margin −738.0% <−999% <−999% —
Operating margin −739.0% <−999% <−999% —
Net margin −737.2% <−999% <−999% —
Free-cash-flow margin −634.8% <−999% <−999% —
Cash flow
Cash from operations −15 −31 −44 −49
Capital spending 0 0 1 0
Free cash flow −15 −31 −45 −49
Stock-based pay 1 2 4 6
Free cash flow after stock pay −16 −33 −49 −55
Balance sheet
Cash 37 75 73 59
Total debt 0 0 0 0
Net debt (negative = net cash) −37 −75 −73 −59
Diluted shares 10m 27m 26m 28m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+20.4%
year over year

Who owns it

Funds buying and selling
Reported value
$172M
Institutions reporting
112
Shares held vs prior quarter
▲ 17.6%
Positions opened / closed
38 / 20

Top buyers and sellers, Q2 2026: 73 institutions bought and 41 sold ; the biggest buyer was Blackrock, Inc (+2.9M shares) and the biggest seller Marshall Wace, LLP (−1.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $48.4M 9.7M 28.2% ▲ 0.1%
Blackrock, Inc. $21.8M 4.4M 12.7% ▲ 190.2%
Sanofi $13.5M 2.7M 7.9% 0.0%
Vanguard Capital Management LLC $11.4M 2.3M 6.6% ▼ 0.1%
Price T Rowe Associates Inc $9.7M 1.9M 5.6% ▲ 5.8%
Geode Capital Management, LLC $6.8M 1.4M 4.0% ▲ 114.9%
State Street Corp $5M 1.0M 2.9% ▲ 273.2%
Dcf Advisers, LLC $3.9M 790K 2.3% ▲ 458.5%
Marshall Wace, LLP $3.7M 732K 2.1% ▼ 63.3%
Connor, Clark & Lunn Investment Management Ltd. $3M 601K 1.7% ▲ 50.2%
Alethea Capital Management, LLC $2.4M 473K 1.4% ▲ 1962.1%
Summit Financial, LLC $2.3M 452K 1.3% ▲ 20.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Immuneering Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $270,336 7 trades by 6 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $270,336 net buying
Insider Date Trade Shares Price Value
Zeskind Benjamin J. PRESIDENT AND CEO June 23, 2026 Buy 2,400 $4.56 $10,948
Hall Brett Matthew CHIEF SCIENTIFIC OFFICER June 15, 2026 Buy 6,035 $4.15 $25,045
Brakewood Harold Eugene Chief Business Officer January 16, 2026 Buy 5,250 $4.76 $24,990
Hall Brett Matthew CHIEF SCIENTIFIC OFFICER January 15, 2026 Buy 2,298 $4.57 $10,502
Schall Thomas J. Director January 15, 2026 Buy 21,645 $4.67 $101,041
Neufeld Leah R CHIEF PEOPLE OFFICER January 13, 2026 Buy 2,626 $4.15 $10,906
Feinberg Peter Director January 12, 2026 Buy 20,000 $4.35 $86,904

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 25, 2027 estimated from the company's past filing pattern, not announced

  • October 29, 2026
  • August 5, 2026
  • May 15, 2026
  • March 6, 2026
  • November 12, 2025
  • August 13, 2025

Recent SEC filings

Data status

When each part of this page on Immuneering Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Immuneering Corp in brief

What does Immuneering Corp do?
Immuneering Corp is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Immuneering Corp's stock ticker?
Immuneering Corp trades under the ticker IMRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Immuneering Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Sanofi. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Immuneering Corp's market cap?
On December 29, 2023, Immuneering Corp's market capitalisation was about $209M and net debt of -$59.4M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Immuneering Corp stock?
Over the last 12 months, Immuneering Corp's directors and officers reported 7 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Immuneering Corp's next earnings date?
Around January 25, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Immuneering Corp announces its own schedule.